[Comment] Neoadjuvant chemotherapy in localised soft-tissue sarcomas: where do we go from here?

In The Lancet Oncology, Alessandro Gronchi and colleagues report a phase 3 trial1 randomly assigning 287 patients with localised, high-risk extremity and trunk wall soft-tissue sarcomas to receive three cycles of histotype-tailored chemotherapy versus a standard control of full-dose chemotherapy with epirubicin plus ifosfamide. With a median follow-up of 12·3 months (IQR 2·75–28·20), the trial was closed prematurely after the third interim analysis for futility because superiority for the histotype-tailored chemotherapy group was not to be expected for both the primary endpoint disease-free survival and the secondary endpoint overall survival.

http://ift.tt/2rBvFx0